anti cd44 monoclonal antibody ro5429083

Drug Overview

The medication known as anti cd44 monoclonal antibody ro5429083 (also identified as RG7356) is an investigational, humanized monoclonal antibody designed to treat aggressive solid tumors and blood cancers. It specifically targets CD44, a cell-surface glycoprotein that plays a central role in tumor growth, survival, and the ability of cancer to spread to other organs.

Developed by Roche/Genentech, RO5429083 was engineered to disrupt the “protective shield” that many cancer cells use to resist treatment. CD44 is often referred to as a “stemness marker” because it is found in high concentrations on Cancer Stem Cells (CSCs)—the resilient cells that are frequently responsible for cancer recurrence after chemotherapy. By targeting these specific cells, RO5429083 aims to achieve a more durable cure than traditional, non-targeted drugs.

• Generic Name: RO5429083.
• Other Names: RG7356.
• Drug Class: Humanized Monoclonal Antibody (IgG1).
• Target: CD44 (Standard isoform and variants).
• Route of Administration: Intravenous (IV) infusion.
• FDA Approval Status: Investigational. As of March 2026, RO5429083 is not FDA-approved. It has completed Phase I clinical trials (e.g., NCT01358903 and NCT01641250). While development as a single agent has been challenging due to the wide presence of CD44 in healthy tissues, it remains a major subject of research for use in combination with other “checkpoint inhibitors” or targeted payloads.

What Is It and How Does It Work? (Mechanism of Action)

The CD44-Hyaluronan Connection

In many tumors, the cell surface is covered in CD44 receptors. These receptors bind to Hyaluronan (HA), a sugar molecule found in the “extracellular matrix” (the scaffolding between cells). When HA binds to CD44, it sends signals into the cancer cell telling it to grow, survive, and migrate.

Molecular Level Mechanisms

1. Ligand Blockade: RO5429083 binds to the “constant” region of the CD44 receptor. This physically prevents Hyaluronan from attaching to the cell, effectively cutting off the growth signal.
2. Internalization: Once the antibody binds to CD44, the cell often pulls the receptor-antibody complex inside (endocytosis), reducing the number of active receptors on the cell surface.
3. ADCC (Antibody-Dependent Cellular Cytotoxicity): As an IgG1 antibody, RO5429083 “flags” the cancer cell for the immune system. Natural Killer (NK) cells recognize the antibody and release toxic proteins to destroy the flagged cell.
4. Disruption of the “Stem Cell Niche”: CD44 helps cancer stem cells stay “anchored” in protective environments within the bone marrow or tumor. By blocking this anchoring, RO5429083 can force these stem cells out into the open where they are more vulnerable to chemotherapy.
5. Inhibition of Metastasis: Because CD44 is required for cancer cells to “crawl” through tissues, the antibody helps prevent the cancer from spreading to distant sites.

FDA Approved Clinical Indications

There are currently no FDA-approved clinical indications for RO5429083.

It has been investigated in clinical trials for the following conditions:

• Acute Myeloid Leukemia (AML): Specifically for patients whose leukemia cells express high levels of CD44.
• Advanced Solid Tumors: Including breast cancer, colorectal cancer, and non-small cell lung cancer (NSCLC).
• Metastatic Pancreatic Cancer: Where CD44 is a known driver of resistance.

Dosage and Administration Protocols

Because RO5429083 is an investigational agent, there is no established “Standard of Care” dose. The following reflect the protocols used during its clinical research phase.

Clinical Efficacy and Research Results

The clinical journey of RO5429083 has provided critical insights into the difficulty of targeting “stemness” markers.

• AML Responses: In a Phase I study of 44 patients with relapsed AML, RO5429083 showed a manageable safety profile and evidence of biological activity, with some patients experiencing a significant reduction in bone marrow “blasts.”
• Solid Tumor Data: In solid tumors, single-agent activity was modest. However, researchers found that the drug was most effective in tumors with a “high HA” environment, suggesting that testing for Hyaluronan levels might help predict who will benefit.
• Pharmacokinetics: The drug showed a “target-mediated” clearance, meaning it was used up quickly by the body as it bound to the vast amount of CD44 present on both cancer and healthy cells, requiring higher doses for effectiveness.

Safety Profile and Side Effects

The primary challenge for RO5429083 is that CD44 is also found on healthy red blood cells and in the skin, leading to specific side effects.

Common Side Effects (>20%):

• Fatigue: A general sense of tiredness.
• Nausea: Usually mild.
• Pyrexia: Temporary fever during or after the infusion.
• Infusion-Related Reactions (IRR): Chills and flushing.

Serious Adverse Events:

• Hematologic Toxicity: Some patients experienced a drop in white blood cells (neutropenia) or platelets.
• Anemia: Because CD44 is involved in the development of red blood cells, a drop in hemoglobin was observed in higher dose cohorts.
• Skin Reactions: Rashes or dryness, as CD44 is important for skin health.
• Hepatotoxicity: Transient elevations in liver enzymes, requiring regular monitoring.

Research Areas

In the fields of Stem Cell and Regenerative Medicine, RO5429083 is a vital tool for studying “Cancer Stem Cell Eradication.” Scientists are using the antibody to understand how CD44 helps “dormant” cancer cells hide in the bone marrow for years before causing a relapse. By combining RO5429083 with Regenerative Stem Cell Therapies, researchers hope to develop a “search and replace” strategy: using the antibody to clear out the cancerous stem cells and then using healthy, engineered stem cells to rebuild the patient’s immune system.

Patient Management and Practical Recommendations

Pre-treatment Tests:

• CD44 Expression Analysis: To confirm the tumor possesses the target.
• Baseline CBC (Complete Blood Count): To monitor for potential anemia or low platelets.
• Hyaluronan (HA) Staining: (In research settings) to determine the density of the tumor “shield.”

Precautions:

• Infusion Monitoring: Close observation for at least 1 hour after the first infusion is required to manage any allergic-like reactions.
• Blood Count Tracking: Regular blood work is necessary to ensure the drug isn’t impacting the production of healthy red blood cells.

“Do’s and Don’ts” List:

• DO report any “shaking chills” or itching during the infusion to your nurse immediately.
• DO keep track of your energy levels; fatigue can be a significant factor with this drug class.
• DON’T ignore sudden shortness of breath or paleness, as these can be signs of treatment-induced anemia.
• DON’T start new herbal supplements without consulting your oncologist, as they may interfere with the drug’s metabolism.

Legal Disclaimer

The information provided is for educational and informational purposes only and does not constitute medical advice. RO5429083 is an investigational agent and is not currently approved by the US Food and Drug Administration (FDA) for any indication. It is available only through participation in approved clinical trials. Always consult with a qualified hematologist-oncologist regarding currently available and approved treatments or your eligibility for research studies.